Cargando…

Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients

Purpose: COVID-19 causes high mortality in Lung Transplant (LTx) patients, therefore vaccination in this population is potentially life-saving. However, the antibody response is impaired after three vaccinations in LTx patients. We questioned whether this response might be increased, and therefore s...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gemert, Johanna, Steenberg, Fleur, van Leer-Buter, Coretta, Kerstjens, Huib, Steenhuis, Willie, Akkerman, Onno, Verschuuren, Erik, Gan, Tji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299568/
https://www.ncbi.nlm.nih.gov/pubmed/37373817
http://dx.doi.org/10.3390/jcm12124125
_version_ 1785064396609814528
author van Gemert, Johanna
Steenberg, Fleur
van Leer-Buter, Coretta
Kerstjens, Huib
Steenhuis, Willie
Akkerman, Onno
Verschuuren, Erik
Gan, Tji
author_facet van Gemert, Johanna
Steenberg, Fleur
van Leer-Buter, Coretta
Kerstjens, Huib
Steenhuis, Willie
Akkerman, Onno
Verschuuren, Erik
Gan, Tji
author_sort van Gemert, Johanna
collection PubMed
description Purpose: COVID-19 causes high mortality in Lung Transplant (LTx) patients, therefore vaccination in this population is potentially life-saving. However, the antibody response is impaired after three vaccinations in LTx patients. We questioned whether this response might be increased, and therefore studied the serological IgG antibody response across up to five doses of the SARS-CoV-2 vaccine. In addition, risk factors for non-response were investigated. Methods: In this large retrospective cohort study, antibody responses were assessed after 1–5 mRNA-based SARS-CoV-2 vaccines in all LTx patients between February 2021 and September 2022. A positive vaccine response was defined as an IgG level ≥ 300 BAU/mL. Positive antibody responses due to COVID-19 infection were excluded from the analysis. Outcome and clinical parameters were compared between responders and non-responders, and multivariable logistic regression analysis was performed to determine the risk factors for vaccine-response failure. Results: The antibody responses of 292 LTx patients were analyzed. Positive antibody response to 1–5 SARS-CoV-2 vaccinations occurred in 0%, 15%, 36%, 46%, and 51%, respectively. During the study period, 146/292 (50%) of the vaccinated individuals tested positive for SARS-CoV-2 infection. The COVID-19-related mortality was 2.7% (4/146), and all four patients were non-responders. Risk factors associated with non-response to SARS-CoV-2 vaccines in univariable analyses were age (p = 0.004), chronic kidney disease (CKD) (p = 0.006), and shorter time since transplantation (p = 0.047). In the multivariable analysis, they were CKD (p = 0.043), and shorter time since transplantation (p = 0.028). Conclusion: A two- to five-dose regime of SARS-CoV-2 vaccines in LTx patients increases the probability of vaccine response and results in a cumulative vaccine response in 51% of the LTx population. LTx patient antibody response to SARS-CoV-2 vaccinations is therefore impaired, especially in patients shortly after LTx, patients with CKD, and the elderly.
format Online
Article
Text
id pubmed-10299568
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102995682023-06-28 Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients van Gemert, Johanna Steenberg, Fleur van Leer-Buter, Coretta Kerstjens, Huib Steenhuis, Willie Akkerman, Onno Verschuuren, Erik Gan, Tji J Clin Med Article Purpose: COVID-19 causes high mortality in Lung Transplant (LTx) patients, therefore vaccination in this population is potentially life-saving. However, the antibody response is impaired after three vaccinations in LTx patients. We questioned whether this response might be increased, and therefore studied the serological IgG antibody response across up to five doses of the SARS-CoV-2 vaccine. In addition, risk factors for non-response were investigated. Methods: In this large retrospective cohort study, antibody responses were assessed after 1–5 mRNA-based SARS-CoV-2 vaccines in all LTx patients between February 2021 and September 2022. A positive vaccine response was defined as an IgG level ≥ 300 BAU/mL. Positive antibody responses due to COVID-19 infection were excluded from the analysis. Outcome and clinical parameters were compared between responders and non-responders, and multivariable logistic regression analysis was performed to determine the risk factors for vaccine-response failure. Results: The antibody responses of 292 LTx patients were analyzed. Positive antibody response to 1–5 SARS-CoV-2 vaccinations occurred in 0%, 15%, 36%, 46%, and 51%, respectively. During the study period, 146/292 (50%) of the vaccinated individuals tested positive for SARS-CoV-2 infection. The COVID-19-related mortality was 2.7% (4/146), and all four patients were non-responders. Risk factors associated with non-response to SARS-CoV-2 vaccines in univariable analyses were age (p = 0.004), chronic kidney disease (CKD) (p = 0.006), and shorter time since transplantation (p = 0.047). In the multivariable analysis, they were CKD (p = 0.043), and shorter time since transplantation (p = 0.028). Conclusion: A two- to five-dose regime of SARS-CoV-2 vaccines in LTx patients increases the probability of vaccine response and results in a cumulative vaccine response in 51% of the LTx population. LTx patient antibody response to SARS-CoV-2 vaccinations is therefore impaired, especially in patients shortly after LTx, patients with CKD, and the elderly. MDPI 2023-06-18 /pmc/articles/PMC10299568/ /pubmed/37373817 http://dx.doi.org/10.3390/jcm12124125 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van Gemert, Johanna
Steenberg, Fleur
van Leer-Buter, Coretta
Kerstjens, Huib
Steenhuis, Willie
Akkerman, Onno
Verschuuren, Erik
Gan, Tji
Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title_full Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title_fullStr Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title_full_unstemmed Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title_short Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients
title_sort increasing antibody responses to five doses of sars-cov-2 mrna vaccine in lung transplant patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299568/
https://www.ncbi.nlm.nih.gov/pubmed/37373817
http://dx.doi.org/10.3390/jcm12124125
work_keys_str_mv AT vangemertjohanna increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT steenbergfleur increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT vanleerbutercoretta increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT kerstjenshuib increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT steenhuiswillie increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT akkermanonno increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT verschuurenerik increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients
AT gantji increasingantibodyresponsestofivedosesofsarscov2mrnavaccineinlungtransplantpatients